Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户:xiaowangjianfeng
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  AIM: To develop a population pharmacokinetic model of adefovir dipivoxil in healthy volunteers and evaluate the effect of individual factors on the pharmacokinetics of adefovir dipivoxil.METHODS: Plasma concentration data collected from 32 healthy Chinese subjects in a Phase Ⅰ clinical study were pooled.Subjects received a single oral dose of 10 mg, 20 mg or 30 mg adefovir dipivoxil,or multiple doses of 10 mg once a day for 9 days.Plasma concentrations of adefovir dipivoxil were measured using a validated liquid chromatography-mass spectrometric method.A nonlinear mixed-effect model was used to analyze the plasma concentration data of adefovir dipivoxil in healthy volunteers and to calculate the relevant parameters as well as inter-and intra-individual variability.RESULTS: The time course of adefovir dipivoxil concentration is best described as a first-order absorption and first-order elimination two-compartment model with lag time.The final estimate of total body clearance (CL) is 56.9 L/h and 78.7 L/h for single and multiple dosing regimen, respectively; the volume distribution of the central compartment (V2) is 106 L; inter-compartmental clearance (Q) is 220 L/h; volume distribution of the peripheral compartment (V3) is 498 L and 800 L for single and multiple dosing regimen, respectively; absorption rate is 0.509 h-1; and lag time is 0.315 h.The inter-individual variabilities of CL and V2 were 22.4% and 58.9%, respectively.The proportional error of residual variability is 14.1% and the additive error is 0.30 mg/L.The final pharmacokinetic model was evaluated using a bootstrap method.CONCLUSIONS: A nonlinear mixed effect model for oral adefovir dipivoxil formulations was developed in healthy Chinese subjects.A multiple dosing regimens may significantly increase the body clearance and volume distribution of the peripheral compartment compared to single dosing regimen.
其他文献
Aims:To evaluate the pharmacokinetics and pharmacodynamics properties of a new recombinant factor Ⅷ (rFⅧ), which was produced and formulated without human or animal-derived protein, and compare it wit
会议
Background: Lopinavir (LPV)/ritonavir (RTV) co-formulation (LPV/r) is a widely used protease inhibitor (PI) based regimen to treat HIV-infection.As with all PIs, the trough concentration (C 12h) is a
会议
Esomeprazole has proved to be effective for the treatment of gastroesophogeal reflux disease (GERD) and ulcers, where intra-gastric pH value is a biomarker to indicate esomeprazole effects on these di
会议
Background: The distribution of renal function and its effect on drug elimination was not well understood in Chinese population, which impeded the clinical therapeutics for Chinese patients as well as
会议
Aim:Rivaroxaban (Bayer Healthcare AG, Wuppertal, Germany), an oral, direct factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disorders has been approved for nonvalvular atri
会议
Aim:Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR) tyrosine kinase.The aim of this study was to investigate the relationship betwe
Purpose:To investigate the pharmacological effects of differenterlotinib (ER) and gemcitabine (GM) combination schedules byin vitro and in vivo experiments and PK/PD models in non-smallcell lung cance
会议
Pediatric drug research is currently one of the new frontiers for clinical pharmacology.With the necessity of pediatric drug research and the special ethical considerations in pediatric clinical trial
会议
INTRODUCTION Drug discovery for central nervous system (CNS) disorders has been challenged with markedly high attrition rate.This has driven extensive preclinical and clinical CNS pharmacokinetic (PK)
会议
Background: Exposure-response model has been established in patients with psoriasis for Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human
会议